Rhythm Pharmaceuticals vs Zevra Therapeutics
RYTM and ZVRA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RYTM and ZVRA compare
Rhythm Pharmaceuticals is the larger company, worth 15 times as much as Zevra Therapeutics ($7.9B against $539M).
Zevra Therapeutics grew revenue faster over the last twelve months (119% versus 53.5% for Rhythm Pharmaceuticals).
Zevra Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.8% compared with −85.6% at Rhythm Pharmaceuticals.
Zevra Therapeutics scores higher on the StockData Score (15 against 5 for Rhythm Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RYTM | ZVRA |
|---|---|---|
| Size and price | ||
| Market cap | $7.9B | $539M |
| Share price | $115.02 | $9.08 |
| Change, 1 year | 17.5% | −3.4% |
| Change, 5 years | 1017% | 8.1% |
| Beta (5Y) | 1.41 | 0.86 |
| Employees | 414 | 61 |
| StockData Score | ||
| Total score | 5 | 15 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 | 3 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 9.8× |
| P/S | 33.0× | 4.0× (better) |
| P/B | 76.9× | 2.5× (better) |
| EV/EBITDA | – | 3.8× |
| P/FCF | – | 16.5× |
| FCF yield | – | 6.1% |
| Fair value | $31.48 | $25.61 |
| Margin of safety | −265% | 64.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 53.5% | 119% (better) |
| Revenue growth, 5Y average | – | 51.6% |
| Net income growth (TTM) | – | 2104% |
| Profitability | ||
| Gross margin | 89.0% | 95.5% (better) |
| Operating margin | −83.6% | 60.5% (better) |
| Net margin | −85.6% | 42.8% (better) |
| FCF margin | – | 24.0% |
| Return on equity | −451% | 34.8% (better) |
| Financial health | ||
| Debt / equity | 1.03 (better) | 0.00 |
| Net debt / EBITDA | – | −2.64 |
| Interest coverage | −10.9× | 14.4× (better) |
| Current ratio | 3.45 | 5.17 (better) |
| Altman Z-score | 16.80 (better) | 4.22 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 112% | 78.5% |
| Held by insiders | 1.1% | 1.2% |
| Insider net buying, 12 months | −$36.0M | −$2.5M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 17.1% | 11.2% |
Go deeper
- RYTM stock overview
- RYTM income statement
- RYTM valuation and score
- ZVRA stock overview
- ZVRA income statement
- ZVRA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.